Tag : NSCLC

CONFERENCE UPDATE

Nivolumab + chemotherapy improves long-term survival outcomes in resectable NSCLC: Final OS analysis from the CheckMate 816 trial
In the final OS analysis of the CheckMate 816 trial, neoadjuvant nivolumab + chemotherapy significantly improved OS in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. With median OS not reached in the nivolumab group vs. 73.7 months in the chemotherapy group , these findings underscore the potential of this combination therapy as a new standard of care.
CONFERENCE UPDATE

First-line lorlatinib continues to show PFS benefit over crizotinib in patients with advanced ALK+ NSCLC: 5-year follow-up of the CROWN study
Lorlatinib is a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) which covers a broader ALK resistance profile than second-generation ALK TKIs. It has previously demonstrated improved PFS and IC activity compared to crizotinib in treatment-naïve patients with advanced ALK+ NSCLC in the ongoing randomized phase 3 CROWN study.
NEWS AND PERSPECTIVE

FDA approves the addition of chemotherapy to osimertinib in EGFRm advanced lung cancer
Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).
NEWS AND PERSPECTIVE

FDA approves amivantamab + chemotherapy in NSCLC with EGFR exon 20 insertion mutations
Alterations in the epidermal growth factor receptor (EGFR) gene occur in up to 40% of non-small cell lung cancers (NSCLCs), among which exon 20 insertions are the third most common type of mutation and account for up to 12% of EGFR-mutated (EGFRm) cases.
INFOGRAPHICS

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC